Reasons for b/tsDMARD cessation and persistence of second line treatment in a large real world rheumatoid arthritis dataset.

CONCLUSION: A large proportion of patients who stopped first-line TNFi therapy received another TNFi despite evidence for longer treatment persistence on second-line b/tsDMARDs with a different mode of action. Lack of efficacy was recorded as the most common reason for making a switch in first-line treatment of RA patients. PMID: 31787605 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31787605?dopt=Abstract

Source: Journal of Rheumatology - December 4, 2019 Category: Rheumatology Tags: J Rheumatol Source Type: research